Kozlova Nina, Cruz Kayla A, Doh Hanna M, Ruzette Antoine A, Willis Nicholas A, Hong Su Min, Gonzalez Raul S, Vyas Monika, Selfors Laura M, Dreyer Stephan, Upstill-Goddard Rosie, Faia Kerrie L, Wenglowsky Steve, Close Josh, Beutel Alica K, Jutric Zeljka, Oliphant Michael U J, Thapa Byanjana, Taylor Martin S, Mustonen Venla, Mangalath Pradeep, Halbrook Christopher J, Grossman Joseph E, Hwang Rosa F, Clohessy John G, Ruskamo Salla, Kursula Petri, Petrova Boryana, Kanarek Naama, Cole Philip A, Chang David K, Nørrelykke Simon F, Scully Ralph, Muranen Taru
bioRxiv. 2025 Jan 25:2025.01.22.634323. doi: 10.1101/2025.01.22.634323.
In pancreatic ductal adenocarcinoma cancer (PDAC) drug resistance is a severe clinical problem and patients relapse within a few months after receiving the standard-of-care chemotherapy. One contributing factor to treatment resistance is the desmoplastic nature of PDAC; the tumours are surrounded by thick layers of stroma composing up to 90% of the tumour mass. This stroma, which is mostly comprised of extracellular matrix (ECM) proteins, is secreted by cancer-associated fibroblasts (CAFs) residing in the tumour microenvironment. However, the mechanistic basis by which the tumour stroma directly contributes to chemoresistance remains unclear. Here, we show that CAF-secreted ECM proteins induce chemoresistance by blunting chemotherapy-induced DNA damage. Mechanistically, we identify N-myc downstream regulated gene 1 (NDRG1) as a key protein required for stroma-induced chemoresistance that responds to signals from the ECM and adhesion receptors. We further show that NDRG1 is a novel DNA repair protein that physically interacts with replication forks, maintains DNA replication and functions to resolve stalled forks caused by chemotherapy. More specifically, NDRG1 reduces R-loops, RNA-DNA hybrids that are known to cause genomic instability. R-loops occur during replication-transcription conflicts in S-phase and after chemotherapy treatments, thus posing a major threat to normal replication fork homeostasis. We identify NDRG1 as highly expressed in PDAC tumours, and its high expression correlates with chemoresistance and poor disease-specific survival. Importantly, knock-out of NDRG1 or inhibition of its phosphorylation restores chemotherapy-induced DNA damage and resensitizes tumour cells to treatment. In conclusion, our data reveal an unexpected role for CAF-secreted ECM proteins in enhancing DNA repair via NDRG1, a novel DNA repair protein, directly linking tumour stroma to replication fork homeostasis and R-loop biology, with important therapeutic implications for restoring DNA damage response pathways in pancreatic cancer.
Drug resistance is a severe clinical problem in stroma-rich tumours, such as pancreatic ductal adenocarcinoma (PDAC), and patients often relapse within a few months on chemotherapy . The stroma, comprised of extracellular matrix (ECM) proteins, is secreted by cancer-associated fibroblasts (CAFs) residing in the tumour microenvironment . Prior work show that ECM proteins provide survival benefits to cancer cells . However, the precise role of CAF-secreted ECM in resistance to DNA damaging chemotherapies remains poorly understood. Here, we link ECM proteins to chemoresistance by enhanced DNA damage repair (DDR). Mechanistically, we identify N-myc downstream-regulated gene 1 (NDRG1) as a key effector downstream of ECM and the integrin-Src-SGK1-signalling axis that mediates enhanced DDR. We show that loss, mutation of conserved His194, or inhibition of NDRG1 phosphorylation by SGK1 lead to replication fork stalling, increased R-loops, and higher transcription-replication conflicts, resulting in genomic instability and sensitivity to chemotherapies. Our analysis of PDAC patient cohorts found that high NDRG1 expression correlates with chemoresistance and poor patient survival. In conclusion, we uncover an unexpected role for CAF-secreted ECM proteins in promoting therapeutic resistance by enhancing DDR and establish NDRG1 as a novel DNA repair protein directly linking tumour stroma to DDR.
在胰腺导管腺癌(PDAC)中,耐药性是一个严重的临床问题,患者在接受标准护理化疗后的几个月内就会复发。治疗耐药的一个促成因素是PDAC的促结缔组织增生特性;肿瘤被厚厚的基质层包围,基质占肿瘤质量的90%。这种主要由细胞外基质(ECM)蛋白组成的基质,是由肿瘤微环境中的癌症相关成纤维细胞(CAF)分泌的。然而,肿瘤基质直接导致化疗耐药的机制基础仍不清楚。在这里,我们表明CAF分泌的ECM蛋白通过减弱化疗诱导的DNA损伤来诱导化疗耐药。从机制上讲,我们确定N- myc下游调节基因1(NDRG1)是基质诱导化疗耐药所需的关键蛋白,它对来自ECM和黏附受体的信号作出反应。我们进一步表明,NDRG1是一种新型的DNA修复蛋白,它与复制叉发生物理相互作用,维持DNA复制,并在解决化疗导致的停滞叉中发挥作用。更具体地说,NDRG1减少R环,即已知会导致基因组不稳定的RNA-DNA杂交体。R环在S期的复制-转录冲突期间以及化疗后出现,因此对正常的复制叉稳态构成重大威胁。我们发现NDRG1在PDAC肿瘤中高度表达,其高表达与化疗耐药和较差的疾病特异性生存率相关。重要的是,敲除NDRG1或抑制其磷酸化可恢复化疗诱导的DNA损伤,并使肿瘤细胞对治疗重新敏感。总之,我们的数据揭示了CAF分泌的ECM蛋白通过新型DNA修复蛋白NDRG1增强DNA修复的意外作用,直接将肿瘤基质与复制叉稳态和R环生物学联系起来,对恢复胰腺癌中的DNA损伤反应途径具有重要的治疗意义。
耐药性是富含基质的肿瘤(如胰腺导管腺癌(PDAC))中的一个严重临床问题,患者在化疗后通常在几个月内复发。由细胞外基质(ECM)蛋白组成的基质,是由肿瘤微环境中的癌症相关成纤维细胞(CAF)分泌的。先前的研究表明,ECM蛋白为癌细胞提供生存益处。然而,CAF分泌的ECM在对DNA损伤化疗的耐药中的精确作用仍知之甚少。在这里,我们通过增强DNA损伤修复(DDR)将ECM蛋白与化疗耐药联系起来。从机制上讲,我们确定N- myc下游调节基因1(NDRG1)是ECM和整合素-Src-SGK1信号轴下游的关键效应因子,介导增强的DDR。我们表明,NDRG1的缺失、保守的His194的突变或SGK1对NDRG1磷酸化的抑制导致复制叉停滞、R环增加和更高的转录-复制冲突,从而导致基因组不稳定和对化疗的敏感性。我们对PDAC患者队列的分析发现,NDRG1高表达与化疗耐药和患者生存率差相关。总之,我们揭示了CAF分泌的ECM蛋白通过增强DDR促进治疗耐药的意外作用,并将NDRG1确立为直接将肿瘤基质与DDR联系起来的新型DNA修复蛋白。